Sage Therapeutics Limited
10646688
Healthy
- Going concern doubt noted in accounts (-10)
Details
Compliance
Last accounts
31/12/2024
small
Next accounts due
30/09/2026
Confirmation statement
Last: 25/02/2026
Due 11/03/2027
Industry
Officers
director · Since 09/10/2025
BUSINESS EXECUTIVE
AMERICAN · UNITED STATES · Age 42
director · Since 09/10/2025
BUSINESS EXECUTIVE
AMERICAN · UNITED STATES · Age 67
Persons with Significant Control
Supernus Pharmaceuticals, Inc.
9715, Key West Avenue, Rockville
Reg: Ein 20-2590184 · Delaware · Corporation
Notified 31/07/2025
Former PSCs
Sage Therapeutics, Inc.
Ceased 31/07/2025
CompanyRankvs 43+ SIC 21200 peers69
Show leaderboard
How is this score calculated?
Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.
Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.
Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.
One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.
Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.
Risk deductions
Going concern doubt: -10 pts
Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.
Going Concern Doubt
and as such no formal decisions on the future of the Company have been made, however there is a material uncertainty that may cast significant doubt upon whether the Company will continue as a going concern. Although it cannot be certain, as no decision has yet been made, management have continued to adopt the going concern basis of accounting in preparing the annual financial statements. P
Key FinancialsYear ending 31/12/2024
Net Worth
£2.1M
Balance sheet strength
Cash
£72k
Cash in the bank
Net Current Assets
£2.1M
Working capital
Current Assets
£2.3M
Current Liabilities
£220k
Debtors
£2.2M
Profit After Tax
£32k
Tax at Year End
EstimatesDerived
| Year | Current Ratio | Implied Profit |
|---|---|---|
| 2024 | 10.33 | +£329k |
| 2023 | 7.40 | +£280k |
| 2022 | 10.85 | — |
Derived from filed accounts. Not audited figures.